<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749979</url>
  </required_header>
  <id_info>
    <org_study_id>Oocyte</org_study_id>
    <nct_id>NCT04749979</nct_id>
  </id_info>
  <brief_title>Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin</brief_title>
  <official_title>Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin in IVF Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estradiol valerate in the form of cycloprogenova™ (white tablet only) was started on day 2 or&#xD;
      3 of cycle with oral dose 4 mg divided on 2 doses in addition to Aspocid 75 mg once daily&#xD;
      with folic acid 500 mcg once daily.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      U/S was done on day 9 or 10 of cycle to assess endometrial thickness, then every other day&#xD;
      until endometrial thickness of 8 mm or more is reached and when endometrial thickness reaches&#xD;
      8 mm or more FET was planned. Progesterone in the form of prontogest™ 400 mg vaginal&#xD;
      suppository twice dTwo to Four Day 5 Embryos was transferred&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 5, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of good quality embryos</measure>
    <time_frame>within 5 months</time_frame>
    <description>how many good quality embryos</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>giving agonist ( eg. decapeptyl )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Giving women agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Giving HCG (eg. choriomon )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Giving women HCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agonist (decapeptyl )</intervention_name>
    <description>giving agonist</description>
    <arm_group_label>giving agonist ( eg. decapeptyl )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCG ( eg. Choriomon )</intervention_name>
    <description>giving HCG</description>
    <arm_group_label>Giving HCG (eg. choriomon )</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS patients according to Rotterdam criteria&#xD;
&#xD;
          -  Female age between 20 and 40 years.&#xD;
&#xD;
          -  Primary or secondary infertility.&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 40 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ovarian endometriosis.&#xD;
&#xD;
               -  Ovarian cysts before induction.&#xD;
&#xD;
               -  Known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>females candidate for ICSI</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Alalfy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algezeera hospitaland National Research Centre ,Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Alalfy</last_name>
    <phone>01002611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aljazeera( Al Gazeera) hospital</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mahmoud Alalfy, PhD</last_name>
      <phone>+201002611058</phone>
      <phone_ext>+2</phone_ext>
      <email>mahmoudalalfy@ymail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

